ScholarIQanswers from OpenAlex
Tokyo Metropolitan Police Hospital
InstitutionResearch output, impact & collaborations
Tokyo Metropolitan Police Hospital is a institution indexed in ScholarIQ from OpenAlex.
What is known about Tokyo Metropolitan Police Hospital?
ScholarIQrecord summary
Tokyo Metropolitan Police Hospital is a research organisation in Tokyo, JP. OpenAlex records 1,071 works and 45,522 citations for it. 290 researchers list it as their most recent affiliation.
How many works does Tokyo Metropolitan Police Hospital have?
ScholarIQindexed works
Tokyo Metropolitan Police Hospital has 1,071 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Tokyo Metropolitan Police Hospital have?
ScholarIQcitation count
Tokyo Metropolitan Police Hospital has 45,522 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Tokyo Metropolitan Police Hospital?
ScholarIQresearcher count
Tokyo Metropolitan Police Hospital has 290 researchers in the ScholarIQ index.
What is the average h-index at Tokyo Metropolitan Police Hospital?
ScholarIQavg h-index
Tokyo Metropolitan Police Hospital has an average h-index of 63 in OpenAlex.
What is the ROR of Tokyo Metropolitan Police Hospital?
ScholarIQror
The ROR for Tokyo Metropolitan Police Hospital is on the source record.
What is the OpenAlex record for Tokyo Metropolitan Police Hospital?
ScholarIQopenalex
The OpenAlex for Tokyo Metropolitan Police Hospital is on the source record.
Who are the most-cited researchers behind Tokyo Metropolitan Police Hospital?
ScholarIQtop researchers by citations
What are the most-cited papers on Tokyo Metropolitan Police Hospital?
ScholarIQmost cited works
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita
A Liver-Derived Secretory Protein, Selenoprotein P, Causes Insulin Resistance
Hirofumi Misu, Toshinari Takamura, Hiroaki Takayama, Hiroto Hayashi, Naoto Nagata, Seiichiro Kurita, Kazuhide Ishikura, Hitoshi Ando, Yumie Takeshita, Tsuguhito Ota, Masaru Sakurai, Tatsuya Yamashita, Eishiro Mizukoshi, Taro Yamashita, Masao Honda, Ken-ichi Miyamoto, Tetsuya Kubota, Naoto Kubota, Takashi Kadowaki, Han-Jong Kim, In‐Kyu Lee, Yasuhiko Minokoshi, Yoshiro Saito, Kazuhiko Takahashi, Yoshihiro Yamada, Nobuyuki Takakura, Shuichi Kaneko
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Hiroshi Katayama, Makoto Ueno, Masafumi Ikeda, Masato Ozaka, Naohiro Okano, Kazuya Sugimori, Akira Fukutomi, Hiroki Hara, Nobumasa Mizuno, Hiroaki Yanagimoto, Keita Wada, Kazutoshi Tobimatsu, Kei Yane, Shoji Nakamori, Hiroyuki Yamaguchi, Akinori Asagi, Seigo Yukisawa, Yasushi Kojima, Ken Kawabe, Yasuyuki Kawamoto, Rie Sugimoto, Tomohisa Iwai, Kazuyoshi Nakamura, Hiroyoshi Miyakawa, Tatsuya Yamashita, A. Hosokawa, Tatsuya Ioka, Naoya Kato, Kazuhiko Shioji, Kyoko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
Arndt Vogel, Shukui Qin, Masatoshi Kudo, Yun Su, Stacie Hudgens, Tatsuya Yamashita, Jung‐Hwan Yoon, Lætitia Fartoux, Krzysztof Simon, Carlos López, Max W. Sung, Kalgi Mody, Tatsuroh Ohtsuka, Toshiyuki Tamai, L. Michelle Bennett, Genevieve Meier, Valery Breder
How much of the research on Tokyo Metropolitan Police Hospital is open access?
ScholarIQopen access share
25%OPEN ACCESS